50 billion antidiabetic drugs market is growing, top 10 brands take over half of the market

Wonderful content: on March 13 this year, AstraZeneca's new diabetes drug, dagreen, was approved by CFDA and became the first sglt-2 inhibitor approved for listing in China On September 21, the listing application of bringer ingelharngren was also approved by CFDA and became the second sglt-2 inhibitor listed in China The domestic market of hypoglycemic drugs is growing again As we all know, diabetes is a chronic disease with high prevalence In recent years, it shows a trend of higher and higher prevalence China is also a large population country, and the diabetes market is certainly not to be underestimated   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> sglt-2 inhibitors are popular Sodium glucose cotransporters are divided into two subtypes: SGLT1 and SGLT2." gliclazin "belongs to SGLT2 inhibitor oral tablets It is the latest drug with hypoglycemic mechanism, weight-loss and antihypertensive effect Its unique feature is that it can specifically inhibit the reabsorption of glucose by the kidney, not depending on the degree of β cell dysfunction or insulin resistance, and the effect will not decline with β cell failure or severe insulin resistance, and will not produce adverse reactions brought by traditional drugs Because of its unique hypoglycemic effect, this kind of medicine will be favored by all kinds of people as soon as it is put on the market At present, the sglt-2 inhibitors that have been listed in the world mainly include: Johnson & Johnson's carglitazine / kenglitazine (trade name invokana), AstraZeneca's farxiga, bringlingham / Lilly's jardiance, antistella's igglitazine / igglitazine, Sinopharm's togglitazine and Dazheng's rugglitazine Among them, only the first three are approved by the FDA, and the last three are approved by the Ministry of health, labor and welfare of Japan The first "gliclazine" drug approved by FDA (approved in March 2013), and the first "gliclazine" drug approved by EMA (approved in November 2012) The sglt-2 inhibitors approved for listing in China are AstraZeneca's dagliejing and bringer Ingelheim's engeliejing, which were approved by CFDA on March 13 and September 21 of this year respectively In addition, domestic enterprises have also launched the development of sglt-2 inhibitors, among which, Hengrui pharmaceutical has the fastest progress in proline henggliptide among the 1.1 "gliclazin" drugs, and has started phase III clinical trials Table 1: type 1.1 "gliclazin" drugs declared and registered in China style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border style: none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the market scale is as high as 50 billion In recent years, with the acceleration of aging, economic development and urbanization, and the increasing prevalence of obesity, the prevalence of diabetes in China has been increasing year by year At present, the number of diabetes patients in China has reached 130 million, ranking the first in the world In addition, less than one-third of the diagnosis rate, less than one-quarter of the treatment rate and one-third of the compliance rate of diabetes in China also make the diabetes market have broad incremental space At present, China is also the country with the fastest growth of diabetes prevalence in the world Figure 1: the market scale of antidiabetic drugs of public medical institutions in China (unit: 10000 yuan) (data source: advanced database intelligent version of minenet) from 2014 to 2016 According to the data of minenet, the market scale of domestic antidiabetic drugs in 2016 reached 48.42 billion yuan, of which the market scale of public medical institutions reached 39.74 billion yuan, an increase of 8.92% year on year In addition, in 2016, in the pattern of terminal hypoglycemic drugs in public medical institutions, insulin and its analogues and oral hypoglycemic drugs were equally divided The market size was 18.86 billion yuan and 18.33 billion yuan respectively, and the market share was basically the same, 47.47% and 46.12% respectively   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Top 10 brands win half of the market." Table 2: Top 10 brands of antidiabetic drugs in public medical institutions in 2016 (data source: intelligent version of minenet advanced database) According to the data of minenet, in 2016, acarbose tablet of Bayer was still the top brand of hypoglycemic drugs in China's public medical institutions, with a sales volume of 3.89 billion yuan, but its market share declined, from 10.77% in 2015 to 9.79% The drug belongs to the class of α - glucosidase inhibitor The second place is Novo Nordisk's aspartic insulin 30 injection In recent years, the sales of the drug has been in a rapid growth stage, reaching 3.81 billion yuan in 2016, up 7.35% year-on-year, with a market share of 9.59% It is expected to surpass acarbose tablet in 2017, becoming the top of the list of hypoglycemic drugs It is worth mentioning that the domestic antidiabetic drugs are gradually breaking through in this field In 2016, three domestic brands were listed in the top 10 brands list, including Acarbose Tablets of Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., recombinant insulin glargine injection of Ganli Pharmaceutical Co., Ltd., and 30 / 70 hybrid recombinant human insulin injection of Tonghua Dongbao Pharmaceutical Co., Ltd Among them, the market scale of Acarbose Tablets of Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd and recombinant insulin glargine injection of Ganli Pharmaceutical Co., Ltd increased by more than 20% year on year.